Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Boehringer Ingelheim
>>
Phase 2
Welcome,
Profile
Billing
Logout
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
3
6
9
12
15
18
21
24
27
30
osoresnontrine
(BI 409306) / Boehringer Ingelheim
BI 1358894
/ Boehringer Ingelheim
BI 730357
/ Boehringer Ingelheim
avenciguat
(BI 685509) / Boehringer Ingelheim
ifebemtinib
(IN10018) / InxMed
BI 54903
/ Boehringer Ingelheim
BI2536
/ Boehringer Ingelheim
BEA 2180 BR
/ Boehringer Ingelheim
BI 836880
/ Boehringer Ingelheim
BI 1026706
/ Boehringer Ingelheim
BI 671800 ED
/ Boehringer Ingelheim
xentuzumab
(BI-836845) / Boehringer Ingelheim
BI 1569912
/ Boehringer Ingelheim
BI 764198
/ Boehringer Ingelheim
BI-44370 TA
/ Boehringer Ingelheim
obrixtamig
(BI 764532) / Boehringer Ingelheim
BI 655064
/ AbbVie, Boehringer Ingelheim
BI-144807
/ Boehringer Ingelheim
BI 836826
/ Boehringer Ingelheim
miptenalimab
(BI 754111) / Boehringer Ingelheim
BI 1265162
/ Boehringer Ingelheim
BI 1819479
/ Boehringer Ingelheim
BI 1839100
/ Boehringer Ingelheim
BI 706321
/ Boehringer Ingelheim
BI 836858
/ Boehringer Ingelheim
BI 770371
/ Boehringer Ingelheim
falbikitug
(AZD0171) / AstraZeneca
Beromun
(tasonermin) / Boehringer Ingelheim
BI 764524
/ Boehringer Ingelheim
BI811283
/ Boehringer Ingelheim
interferon omega
(ITCA 638) / Intarcia, Boehringer Ingelheim
somatotaxin
(FX125L) / Boehringer Ingelheim
BI 3720931
/ Boehringer Ingelheim
BI 765128
/ Boehringer Ingelheim
NBE-002
/ Sotio, Boehringer Ingelheim
SOT102
/ Sotio, Boehringer Ingelheim
T3P-Y058-739
/ Boehringer Ingelheim
XP-102
/ Xynomic
